Randomized Study of Obicetrapib as an Adjunct to Statin Therapy
Status:
Completed
Trial end date:
2021-08-30
Target enrollment:
Participant gender:
Summary
This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study
to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to
high-intensity statin therapy.